Anti-CD19 chimeric antigen receptor T-cell therapies - Wuhan Bio Raid Biotechnology

Drug Profile

Anti-CD19 chimeric antigen receptor T-cell therapies - Wuhan Bio Raid Biotechnology

Alternative Names: anti-CD19 CAR-T therapy

Latest Information Update: 23 Nov 2016

Price : $50

At a glance

  • Originator Wuhan Bio-Raid Biotechnology
  • Class CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown B cell lymphoma

Most Recent Events

  • 14 Nov 2016 Clinical trials in B-cell lymphoma (Second-line therapy or greater, Refractory metastatic disease) in China (unspecified route) (ChiCTR-OPN-16009847)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top